Funding
← Back to your selection

NAVER D2SF

Activity from announced rounds

Activity in this selectionOct 18, 2026 · Jul 21, 2026

NAVER D2SF is NAVER’s startup investment organization, identified through official materials for ImpriMed and NdotLight.

Recorded funding activity

ImpriMed combines live-cell drug testing with clinical data. NdotLight generates simulation-ready 3D data, while F4GE structures factory information for industrial buyers. The organization retains its identity separately from NAVER Ventures and the parent.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$20.6M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Series B1
Undisclosed1

By primary sector

Defense tech1
Healthtech1
Robotics1

By country

South Korea3

Rounds

3 in this selection
ImpriMed

A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.

$10MSeries A2 bridge
Participant
F4GE

Standardizes Korean factory data to connect manufacturers with global defense and industrial buyers

Role not disclosed
NdotLight

Generates simulation-ready 3D data for physical AI training

₩15BSeries B
Role not disclosed